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Background. The view that hemoglobin levels in peritoneal
dialysis patients should be maintained at 11 to 12 g/dL is based
largely on the results of studies in hemodialysis patients.
Methods. We studied 13,974 erythropoietin-treated Medi-
care patients who initiated peritoneal dialysis between 1991 and
1998. Mean hemoglobin levels for the first 6 months of the study
and, subsequently, time to first hospitalization and death during
a 2-year follow-up were determined.
Results. The percentages of patients with hemoglobin levels
of <10, 10 to 10.9, 11 to 11.9, and ≥12 g/dL were 24.6%, 40.6%,
27.6%, and 7.2%, respectively. First-hospitalization and death
rates, respectively, were 109.5 and 21.6 per 100 patient-years in
nondiabetic patients, and 152.9 and 31.5 in diabetic patients. In
nondiabetic patients, adjusted hospitalization hazard ratios for
hemoglobin levels of <10, 10 to 10.9, 11 to 11.9 (reference cate-
gory), and ≥12 g/dL were 1.29 (P < 0.0001), 1.15 (P < 0.0001),
1, and 0.98 (NS), respectively. The corresponding adjusted mor-
tality hazard ratios were 1.43 (P < 0.0001), 1.13 (P < 0.05), 1,
and 1.14 (NS). In diabetic patients, hazard ratios of 1.26 (P <
0.0001), 1.07 (NS), 1, and 0.82 (P < 0.01) were observed for
hospitalization, and 1.34 (P < 0.0001), 1.18 (P < 0.01), 1, and
0.92 (NS) for mortality.
Conclusion. In peritoneal dialysis patients, anemia is asso-
ciated with hospitalization and mortality in a manner sup-
porting current Kidney Dialysis Outcomes Quality Initiative
(K/DOQI) hemoglobin targets. In addition, hemoglobin levels
of ≥12 g/dL are associated with lower hospitalization rates in
diabetic patients.
Survival associations in observational studies, and en-
hanced quality of life and partial regression of left ven-
tricular hypertrophy in controlled trials have led to the
Kidney Dialysis Outcomes Quality Initiative (K/DOQI)
guideline that hemoglobin levels in patients with chronic
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kidney disease be maintained at 11 to 12 g/dL [1]. This
guideline has been suggested for all patients with chronic
kidney disease, irrespective of disease severity and mode
of renal replacement therapy. The evidence support-
ing these guidelines has been extrapolated largely from
hemodialysis populations [2–4]. However, hemodialy-
sis and peritoneal dialysis are very different therapies,
and the validity of such extrapolation has not been de-
termined. Our study attempted to address this gap in
knowledge regarding the treatment of peritoneal dialysis
patients.
METHODS
Objectives
The objectives of this study were to study the asso-
ciations between hemoglobin levels averaged over the
6 months following enrollment in the Renal Beneficiary
Utilization System of the Centers for Medicare & Med-
icaid Services, and subsequent first-hospitalization and
death rates.
Design
This was a retrospective cohort study with two main
phases: a 6-month entry period following enrollment
with the Renal Beneficiary Utilization System, during
which time hemoglobin levels were obtained, and a
2-year follow-up period that tracked the first subsequent
hospitalization and death.
Subjects
The study population consisted of patients who: (1) ini-
tiated peritoneal dialysis between 1991 and 1998; (2) were
20 years old or older at initiation of peritoneal dialysis;
(3) were receiving peritoneal dialysis on day 91 of dial-
ysis [5]; (4) survived for at least 9 months on peritoneal
dialysis (to allow a 6-month period after registration with
the Renal Beneficiary Utilization System, which uses a
90-day after-dialysis inception enrollment rule); (5) had
more than two erythropoietin claims during the 6-month
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Table 1. Baseline patient characteristics by diabetes status and mean hemoglobin valuea
Nondiabetic Diabetic
N = 8267 (59.2%) N = 5707 (40.8%)
Hemoglobin value g/dL Hemoglobin value g/dL
<10 10–10.9 11–11.9 ≥12 <10 10–10.9 11–11.9 ≥12
All 24.3c 40.2c 28.3c 7.2c P valueb All 25.1d 41.1d 26.7d 7.1d P valueb
Age years <0.0001 <0.0001
20–44 20.3 30.6 18.9 15.5 12.9 15.4 20.2 14.7 13.1 11.6
45–64 23.2 25.8 23.4 22.0 18.3 37.4 40.2 38.0 35.3 31.7
65–74 34.9 28.7 36.0 37.4 40.2 36.8 33.4 36.8 38.5 42.3
≥75 21.5 14.9 21.8 25.2 28.6 10.4 6.2 10.5 13.2 14.4
Gender 0.0025 0.0022
Male 54.3 51.8 53.9 55.7 59.8 47.5 44.2 47.0 50.2 52.2
Female 45.7 48.2 46.1 44.3 40.2 52.5 55.8 53.1 49.8 47.8
Race <0.0001 <0.0001
White 71.8 61.0 73.3 77.7 77.3 72.0 67.6 72.5 74.2 75.7
Black 23.3 34.6 21.9 17.2 17.1 21.1 25.6 20.8 18.6 16.6
Other 4.9 4.4 4.8 5.1 5.6 6.9 6.8 6.7 7.2 7.7
Comorbidity
ASHD 44.1 38.7 44.2 46.6 51.1 <0.0001 54.9 51.8 55.1 55.4 63.1 0.0008
Cancer 21.4 20.4 21.9 20.8 24.2 NS 15.0 13.3 15.1 16.0 16.6 NS
Other cardiac 56.9 55.0 57.5 57.1 59.8 NS 59.6 60.1 59.6 58.2 63.6 NS
CHF 43.9 43.4 44.0 43.7 45.2 NS 57.2 59.4 56.6 55.4 59.2 NS
COPD 23.0 20.0 23.2 24.8 24.9 0.0013 18.9 18.1 19.0 18.8 21.3 NS
CVA/TIA 20.0 18.7 20.5 19.7 22.9 NS 24.6 22.9 24.4 26.0 26.5 NS
Biliary 7.1 7.5 7.5 6.8 5.6 NS 7.9 8.7 7.0 8.7 6.4 NS
GI bleeding 19.3 21.6 18.8 17.9 19.8 0.0156 18.3 19.0 19.0 16.9 17.3 NS
Liver disease 23.4 21.5 22.9 24.7 28.2 0.0022 23.8 23.6 23.0 24.5 26.7 NS
PVD 33.3 29.5 33.9 34.4 38.5 <0.0001 39.7 37.2 39.2 40.9 46.3 0.0065
Abbreviations are: ASHD, atherosclerotic heart disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident;
GI, gastrointestinal; NS, not statistically significant; PVD, peripheral vascular disease; TIA, transient ischemic attack.
aWith the exception of italicized items, descriptive statistics are presented as percentages within each hemoglobin group, so that columns add up to 100%.
bComparing the characteristics in the first column according to hemoglobin category, using the v 2 test.
cPercentage of the total nondiabetic population in this hemoglobin group.
dPercentage of the total diabetic population in this hemoglobin group.
entry period (i.e., months 4 to 9 of peritoneal dialysis);
and (6) were primary Medicare recipients throughout the
entry period (defined as receiving payments of at least
$675 per month for dialysis and excluding those enrolled
in a health maintenance organization [5]).
Measurements
The Renal Beneficiary Utilization System identifi-
cation and death notification files and Centers for
Medicare & Medicaid Services Institutional Inpatient
Standard Analytical Files were used. Comorbid condi-
tions present before the 2-year follow-up period were
identified from Medicare Part A institutional claims and
Part B physician/supplier claims using International Clas-
sification of Diseases, Ninth Revision, Clinical Modifi-
cation (ICD-9-CM), and Physicians’ Current Procedural
Terminology (CPT) codes. Hematocrit data, taken from
the Medicare erythropoietin claims files, were averaged
over the 6-month entry period, and hematocrit averages
were multiplied by 0.33 to generate hemoglobin values in
g/dL.
Analysis
Cox proportional hazards analysis was used to study
the association between mean hemoglobin levels and sub-
sequent hospitalization-free and overall survival times.
Adjustment was made for demographic and comorbid
characteristics, and diabetic and nondiabetic populations
were analyzed separately. A switch to hemodialysis or
renal transplantation was a censoring event for both out-
comes, and follow-up ended at 2 years.
We also examined time to first cardiovascular disease
hospitalization and first noncardiovascular hospitaliza-
tion in diabetic and nondiabetic patients, with cardio-
vascular disease defined as atherosclerotic heart disease,
congestive heart failure, cerebrovascular disease, tran-
sient ischemic attack, or peripheral vascular disease. All
analyses were performed using SAS for Windows, version
8.2 (SAS Institute, Cary, NC, USA).
RESULTS
Patient characteristics
Table 1 shows the baseline characteristics of the 13,974
study subjects, 40.8% of whom had diabetes mellitus.
Among nondiabetic patients, the mean age was 61 years,
54.3% of the patients were male, and 71.8%, 23.3%, and
4.9% of the patients were white, black, and of other
race, respectively. Among diabetic patients, the corre-
sponding findings were 60 years, 47.5%, and 72.0%,
21.1%, and 6.9%, respectively. Table 1 also shows patient
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Table 2. Unadjusted all-cause mortality and first hospitalization: rate (SE) per 100 patient-years
Hemoglobin value g/dL
All patients <10 10–10.9 11–11.9 ≥12
Mortality
All 25.4 (0.39) 26.9 (0.84) 25.8 (0.62) 23.4 (0.70) 26.2 (1.46)
Nondiabetics 21.6 (0.46) 22.9 (0.99)a 21.5 (0.73) 20.1 (0.83) 24.3 (1.80)a
Diabetics 31.5 (0.71) 33.4 (1.51)a 32.7 (1.13)a 28.8 (1.27) 29.2 (2.47)
First hospitalization
All 124.6 (1.17) 148.2 (2.79) 127.5 (1.87) 110.3 (2.00) 102.4 (3.71)
Nondiabetics 109.5 (1.36) 128.3 (3.20)a 113.0 (2.20)a 96.0 (2.28) 95.2 (4.51)
Diabetics 152.9 (2.21) 186.3 (5.33)a 153.9 (3.45)a 139.1 (3.91) 114.6 (6.45)a
aP < 0.05 using the Poisson regression model, with hemoglobin category 11 to 11.9 g/dL as reference.
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Fig. 1. Mortality hazard ratios (and 95% CI),
according to hemoglobin level. Hemoglobin
levels of 11 to 11.9 g/dL were the reference cat-
egory. Adjustment was made for age, gender,
race, and the presence of atherosclerotic heart
disease, cancer, other cardiac disease, con-
gestive heart failure, chronic obstructive pul-
monary disease, stroke, or transient ischemic
attack, biliary disease, gastrointestinal bleed-
ing, liver disease, and peripheral vascular dis-
ease. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗∗P < 0.0001.
characteristics by mean hemoglobin level during the 6-
month entry period. The percentages of patients with
hemoglobin values of <10, 10 to 10.9, 11 to 11.9, and
≥12 g/dL were 24.3%, 40.2%, 28.3%, and 7.2%, respec-
tively, for nondiabetics, and 25.1%, 41.1%, 26.7%, and
7.1% for diabetics. For all patients, the percentages of
patients with hemoglobin levels of <10, 10 to 10.9, 11 to
11.9, and ≥12 g/dL were 24.6%, 40.6%, 27.6%, and 7.2%,
respectively.
Among nondiabetic patients, older age, male gender,
white race, the presence of atherosclerotic cardiovascu-
lar disease, chronic obstructive pulmonary disease, and
peripheral vascular disease, and the absence of gastroin-
testinal bleeding were associated with higher hemoglobin
levels. In the diabetic population, higher hemoglobin lev-
els were associated with older age, male gender, white
race, and the presence of atherosclerotic heart disease
and peripheral vascular disease.
Outcomes
Table 2 shows unadjusted all-cause mortality rates, with
hemoglobin levels of 11 to 11.9 g/dL as the reference cat-
egory. Rates in nondiabetic patients were higher in those
with hemoglobin values of <10 and ≥12 g/dL. Rates in
diabetic patients were highest in those with hemoglobin
values of <10 g/dL, followed by those with levels of 10
to 10.9 g/dL, while those in the 11 to 11.9 and ≥12 g/dL
categories had similar mortality rates.
Table 2 also shows first-hospitalization rates, with
hemoglobin levels of 11 to 11.9 g/dL as the reference cat-
egory. Rates in nondiabetic patients were associated with
hemoglobin levels of <10 g/dL, followed by levels of 10
to 10.9 g/dL, while those in the 11 to 11.9 and ≥12 g/dL
categories had similar rates. Rates in the diabetic pop-
ulation declined monotonically with each increment in
hemoglobin category.
Figure 1 depicts the mortality hazard ratio associ-
ated with each hemoglobin category, using 11 to 11.9
g/dL as the reference group. After adjustment for
demographic characteristics and comorbid conditions,
associations were similar in nondiabetic and diabetic pa-
tients, with hemoglobin values of <10 g/dL and 10 to
10.9 g/dL associated with higher mortality (compared
with hemoglobin values of 11 to 11.9 g/dL), while values
of ≥12 g/dL had similar mortality associations.
Figure 2 depicts the associations between hemoglobin
level and adjusted first-hospitalization rate. Hemoglobin
values of <10 g/dL and 10 to 10.9 g/dL were associ-
ated with higher hospitalization rates (compared with
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Fig. 2. First-hospitalization hazard ratios
(and 95% CI), according to hemoglobin
level. Hemoglobin levels of 11 to 11.9 g/dL
were the reference category. Adjustment
was made for age, gender, race, and the
presence of atherosclerotic heart disease,
cancer, other cardiac disease, congestive
heart failure, chronic obstructive pulmonary
disease, stroke, or transient ischemic attack,
biliary disease, gastrointestinal bleeding,
liver disease, and peripheral vascular disease.
∗∗P < 0.01, ∗∗∗∗P < 0.0001.
hemoglobin values of 11 to 11.9 g/dL, the reference cat-
egory). While the hazard ratio reached a plateau at 11
to 11.9 g/dL in the nondiabetic population, hemoglobin
levels of ≥12 g/dL were associated with a further reduc-
tion in first-hospitalization rate in the diabetic population.
The associations of hemoglobin levels with cardiovascu-
lar and noncardiovascular admission rates were very sim-
ilar to the associations of hemoglobin levels with overall
admission rates (data not shown).
DISCUSSION
Using adjusted models, we found anemia to be an an-
tecedent association of mortality and hospitalization in
peritoneal dialysis patients, in a manner supporting cur-
rent K/DOQI hemoglobin targets of 11 to 12 g/dL for
patients with chronic kidney disease. Hemoglobin levels
were higher in those with greater degrees of comorbidity,
and adjustment for comorbidity led to considerable dif-
ferences in mortality associations, especially in the non-
diabetic population. In addition, hemoglobin levels of
≥12 g/dL were associated with lower adjusted hospitaliza-
tion rates in diabetic patients. Our results are consistent
with the findings of observational studies in hemodialysis
patients [2–4, 6, 7], and studies of patients with congestive
heart failure [8–11]. It bears repeating that most of the
observational data used in this study were accrued before
publication of the K/DOQI guidelines in 1997 [1].
Making treatment recommendations for one patient
population on the basis of data extrapolated from another
is inherently unsatisfactory. There can be little doubt that
peritoneal dialysis and hemodialysis are highly dissimilar
therapies in many respects. For example, with regard to
anemia and its treatment, it is a common finding that peri-
toneal dialysis patients tend to be less anemic and more
sensitive to erythropoietic agents than their hemodialy-
sis counterparts [12]. Potential biological mechanisms for
these differences include better preservation of residual
renal function in peritoneal dialysis patients, blood loss
during hemodialysis sessions, differing patterns of ure-
mic toxin removal, less hemodilution, less iron deficiency,
and less inflammation [12]. In addition, the associations
between hemoglobin level and outcome in hemodialysis
patients are based on samples drawn immediately before
hemodialysis, which is usually the zenith in the extracel-
lular fluid volume expansion-contraction cycle. Diurnal
fluid shifts are less dramatic in peritoneal dialysis patients.
Because of its observational, nonexperimental design,
this study cannot determine whether associations be-
tween anemia and adverse outcomes are causal or non-
causal. Anemia has physiologic consequences, including
peripheral vasodilation, increased venous return, cardiac
enlargement, and increased cardiac output [13]. It is plau-
sible that these mechanisms contribute to cardiovascular
morbidity and mortality. Controlled trials in hemodial-
ysis patients have shown that partial correction of renal
anemia improves quality of life, especially in terms of
fatigue, depression, and exercise capacity, and leads to
partial regression of left ventricular hypertrophy [14, 15].
More recent randomized trials suggest that full correction
of anemia leads to further improvement in quality of life
without further regression of left ventricular hypertrophy
[16–18], while the only adequately powered trial to date
showed no survival benefit of full correction of renal ane-
mia, and a clear tendency toward harm in terms of dialy-
sis access preservation [19]. The potential for aggressive
hemoglobin targets to lead to harm should be respected,
given the scope of the latter study and the low likelihood
of replicating it in peritoneal dialysis patients. Of the eight
major types of analysis presented here (diabetic and non-
diabetic, hospitalization and death, unadjusted and ad-
justed), hemoglobin levels of ≥12 g/dL were associated
with lower event rates in three, and higher event rates
in five. With regard to statistically significant differences,
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larger event rates were seen in one, and smaller event
rates in two of the eight analyses. Overall, these findings
are not consistent enough to endorse hemoglobin levels
of ≥12 g/dL. It is also plausible that associations between
anemia and adverse outcomes are not causal. Anemia, for
example, could cosegregate with declining native renal
function, major ongoing illness, sepsis, chronic inflamma-
tion, or chronic fluid overload. It could be a marker for
unmeasured comorbidity or more severe levels of mea-
sured comorbidity. The results of our adjusted analyses
suggest that the association between anemia and outcome
seen in this study cannot be explained by these known
comorbidities.
Our analysis plan measured hemoglobin levels in the
first 6 months and examined outcomes in the follow-
ing 2 years. Classic epidemiologic teaching suggests that
the period when candidate risk factors are measured
should be separated in time from the period when out-
comes are measured. Although methods (such as using
serial hemoglobin levels as a segmented, time-dependent
covariate) exist that can circumvent the problem of im-
posing an arbitrary entry period, as we did, exposure and
outcome periods are mixed using these alternative meth-
ods; this may be a source of bias if events occurring before
death can lead to a decline in hemoglobin level, which
is likely. Imposing an arbitrary entry period necessarily
means that a subset of patients with an inherent survival
bias is selected; the extent of this problem increases with
longer entry periods. The 6-month entry period in this
study was chosen to meet the competing needs to mini-
mize selection bias, separate exposure and outcome, and
accommodate a belief that risk increases with exposure.
Our study has limitations. It was a retrospective anal-
ysis, and comorbidity was measured from administrative
claims data. It was limited to patients using Medicare
as primary payer, and submission of claims for erythro-
poietin was a study prerequisite. It is impossible to tell,
therefore, if anemia is associated with a similar outcome
profile in patients who do not require erythropoietin,
those who require it intermittently, and those in whom
the requirement is not addressed. In addition, the study
lacks information regarding parameters of iron stores,
residual renal function, adequacy of dialysis, blood pres-
sure, nutrition, and other medical treatments at the time
when the hemoglobin value was estimated.
CONCLUSION
We believe the study has positive features, however.
Although retrospective, it used an inception cohort de-
sign, and hemoglobin levels were time averaged. The risk
exposure period and the outcome measurement periods
were separated in time. It is probably fair to say that co-
morbidity adjustment was relatively extensive. The study
sample size was large and represents the national expe-
rience within the United States. Within its limitations,
the study showed that anemia, usually an easily treat-
able condition, is associated with adverse outcomes in
peritoneal dialysis patients, in a manner supporting cur-
rent K/DOQI hemoglobin targets. Hemoglobin levels are
highly modifiable in most patients with chronic kidney
disease. Observational studies like ours may be a useful
aid to hypothesis generation and sample size estimation.
Only randomized, controlled trials, however, can truly
define the role of anemia correction in peritoneal dialysis
patients, and these are sorely needed.
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